Page last updated: 2024-11-12
maltooctaose
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
maltooctaose: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10887738 |
| CHEBI ID | 152439 |
| MeSH ID | M0265341 |
Synonyms (10)
| Synonym |
|---|
| glc(a1-4)glc(a1-4)glc(a1-4)glc(a1-4)glc(a1-4)glc(a1-4)glc(a1-4)glc |
| CHEBI:152439 |
| wurcs=2.0/2,8,7/[a2122h-1x_1-5][a2122h-1a_1-5]/1-2-2-2-2-2-2-2/a4-b1_b4-c1_c4-d1_d4-e1_e4-f1_f4-g1_g4-h1 |
| alpha-d-gluco-hexopyranosyl-(1->4)-alpha-d-gluco-hexopyranosyl-(1->4)-alpha-d-gluco-hexopyranosyl-(1->4)-alpha-d-gluco-hexopyranosyl-(1->4)-alpha-d-gluco-hexopyranosyl-(1->4)-alpha-d-gluco-hexopyranosyl-(1->4)-alpha-d-gluco-hexopyranosyl-(1->4)-d-gluco-he |
| 6156-84-9 |
| maltooctaose |
| W-203297 |
| mfcd05865015 |
| (2r,3r,4s,5s,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2r,3s,4r,5r,6r)-6-[(2r,3s,4r,5r,6r)-6-[(2r,3s,4r,5r,6r)-6-[(2r,3s,4r,5r,6r)-6-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3s,4r,5r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihy |
| (2r,3r,4s,5s,6r)-2-{[(2r,3s,4r,5r,6r)-6-{[(2r,3s,4r,5r,6r)-6-{[(2r,3s,4r,5r,6r)-6-{[(2r,3s,4r,5r,6r)-6-{[(2r,3s,4r,5r,6r)-6-{[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-{[(2r,3s,4r,5r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}oxan-3-yl]oxy} |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Both the length and dispensation of these branches are critical in defining the structure, density, and relative bioavailability of the storage polysaccharide." | ( The Structure of Maltooctaose-Bound Bingham, C; Chiou, J; Fawaz, R; Geiger, JH; Gilbert, L; Nayebi, H; Park, SH, 2023) | 1.25 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| oligosaccharide | A compound in which monosaccharide units are joined by glycosidic linkages. The term is commonly used to refer to a defined structure as opposed to a polymer of unspecified length or a homologous mixture. When the linkages are of other types the compounds are regarded as oligosaccharide analogues. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 20.10
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.10) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||